Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Aug;44(8):568-570.
doi: 10.1016/j.it.2023.06.007. Epub 2023 Jul 12.

MAdCAM-1: a newly identified microbial 'gut check' for T cells

Manoj Chelvanambi  1 , Jennifer A Wargo  2
Affiliations
Comment

MAdCAM-1: a newly identified microbial 'gut check' for T cells

Manoj Chelvanambi et al. Trends Immunol. 2023 Aug.

Abstract

The gut microbiome influences the response, resistance, and toxicity of cancer immunotherapy, but the underlying mechanisms remain unknown. Fidelle et al. identify intestinal MAdCAM-1 as a mechanistic target through which gut dysbiosis blunts antitumor immunity, with opportunities for putative therapeutic intervention.

Keywords: MAdCAM-1; antitumor immunity; gut dysbiosis; gut microbiome; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.A.W. is an inventor of US patent application PCT/US17/53.717, submitted by the University of Texas MD Anderson Cancer Center, which covers methods to enhance immune checkpoint blockade responses by modulating the microbiome; reports compensation for the speaker's bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physicians' Education Resource, MedImmune, Exelixis, and Bristol Myers Squibb; and has served as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Micronoma, OSE therapeutics, Merck, and Everimmune. J.A.W. receives stock options from Micronoma and OSE therapeutics.

Comment on

  • A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.
    Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, Mbogning Fonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, Drubay D, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, Zitvogel L. Fidelle M, et al. Science. 2023 Jun 9;380(6649):eabo2296. doi: 10.1126/science.abo2296. Epub 2023 Jun 9. Science. 2023. PMID: 37289890

LinkOut - more resources